Suggestions
Aaron Morris
Co-Founder at Allvision IO
Aaron Morris is the Co-Founder and CEO of PostEra, a biotechnology company focused on using artificial intelligence to accelerate drug discovery.13 He has a strong background in mathematics, having completed his postgraduate studies in Applied Mathematics at Oxford University.3
Prior to founding PostEra in October 2019, Aaron spent five years at Goldman Sachs in London, where he worked as a Data Scientist and Trader.13 His roles at Goldman Sachs included:
- Equities Trading: Event-Driven Quant (October 2017 - October 2019)
- Equity Derivatives Trader (June 2016 - September 2017)
- Risk Analyst (June 2014 - May 2016)1
Aaron's educational background includes:
- MSc with Distinction in Applied Mathematics from the University of Oxford (2013 - 2014)
- BSc with First Class Honours in Mathematics from Durham University (2010 - 2013)1
At PostEra, Aaron leads a team that uses machine learning to accelerate medicinal chemistry and bring more cures to patients.25 The company has raised significant funding and established partnerships with major pharmaceutical companies like Amgen and Pfizer.24
Highlights
We've got a bunch of roles PostEra is still interviewing for if anyone is excited by the idea of using machine learning to develop cures for diseases, alongside this excellent bunch of jungle explorers.
Lead Software Engineer ➡ https://lnkd.in/eMcDwCmq
In vivo Pharmacologist ➡ https://lnkd.in/e_Sfeqii
#hiring #ai #drugdiscovery #biotech #pharma #startup
The COVID Moonshot effort has just been published in Science! Alongside fantastic collaborators, PostEra helped launch this effort back in March 2020 and it soon became the world's largest open-science effort to develop non-profit COVID antivirals.
Hundreds of scientists and their organisations contributed ideas and resources, and the combination of crowdsourcing, machine learning, exascale molecular simulations, and high-throughput structural biology and chemistry helped the project make rapid progress.
The work resulted in a lead compound demonstrating in vivo efficacy in preclinical SARS-CoV-2 infection models. The compound continues to show an excellent safety profile based on its in vitro selectivity profile and interim in vivo safety pharmacology results. Scale-up chemistry and kilo-scale GMP manufacturing is ongoing to allow for comprehensive evaluation of the compound in non-GLP and GLP safety models.
Read the full article ➡ https://lnkd.in/eGCM5YEe
Read more on COVID Moonshot ➡ https://lnkd.in/eV4QTNCf
#science #openscience #machinelearning #covid #moonshot
